KIST/PU Nanostructured Heparin Derivatives as an Angiogenesis Inhibitor
07 Dec 2011 | Online Presentations | Contributor(s): Youngro Byun
Although low molecular weight heparin (LMWH) has been known to regulate angiogenesis, tumor growth and metastasis, the administration of heparin for treating cancer is limited in clinical application due to its unsatisfactory therapeutic effects and a strong anticoagulant activity, which induces...
KIST/PU The Professor’s Challenge: To commercialize or not, that is the question?
06 Dec 2011 | Online Presentations | Contributor(s): J. Paul Robinson
Outline:Outline the Professors DilemmaShow what the normal criteria for research project direction isDiscuss the Corporate perspectiveDiscuss an example of failed innovationDemonstrate how time can impact an innovative ideaConclusions
KIST/PU Designing a Research Program Around Unmet Clinical Needs
06 Dec 2011 | Online Presentations | Contributor(s): Alyssa Panitch
KIST/PU Theragnosis – A New Paradigm of Personalized Medicine
06 Dec 2011 | Online Presentations | Contributor(s): Ick Chan Kwon
Companion Diagnosis, based on pharmacogenomics, has been recognized as one of most important key representatives of personalized medicine. However, Companion Diagnosis does not provide any clues in developing new ways of therapeutics but it only provides a best choice of drugs based on given...